Stratton Management’s iShares Biotechnology ETF IBB Stock Holding History

Stratton Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$880K	Hold	7,800	–	–	0.11%	151
2015 Q3	$789K	Buy	+7,800	New	+$936K	0.09%	165

Other funds holding IBB

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Stratton Management's IBB Position: Q4 2015 in Review

Stratton Management held its iShares Biotechnology ETF (IBB) position steady in Q4 2015 at 7,800 shares worth $880K. The position accounts for 0.11% of the portfolio, ranked #151.

Stratton Management first reported a position in IBB in Q3 2015 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold IBB as of Q4 2015.

Stratton Management held 7,800 shares of iShares Biotechnology ETF worth $880K as of Q4 2015.
Stratton Management left its iShares Biotechnology ETF share count unchanged in Q4 2015.
iShares Biotechnology ETF made up 0.11% of Stratton Management's portfolio in Q4 2015, its #151 holding.
Stratton Management first reported a position in iShares Biotechnology ETF in Q3 2015 and has held it in 2 quarters since.
432 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2015.

Based on Stratton Management's 13F filing for Q4 2015, filed 11 Feb 2016.